Study #2023-0579
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG 509 in subjects with metastatic castration-resistant Prostate Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
AMG 509, Abiraterone, Enzalutamide
Description
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Part 2 is now closed to accrual.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Cancer
Study phase:
Phase I
Physician name:
Bilal Siddiqui
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-888-994-0731
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.